low - Clinical trial timelines and FDA regulatory processes are largely insulated from GDP fluctuations. However, ability to raise capital is indirectly affected by risk appetite in equity markets during recessions. Patient enrollment can be marginally impacted by healthcare utilization patterns during severe economic downturns.

Rising interest rates negatively impact Candel through two mechanisms: (1) higher discount rates compress the present value of distant future cash flows (approval is years away), making long-duration biotech assets less attractive relative to bonds, and (2) risk-off sentiment in rate-hiking cycles reduces investor appetite for speculative, cash-burning clinical-stage companies. The company's minimal debt (0.08 D/E) means direct financing cost impact is negligible, but equity financing becomes more expensive and dilutive.

growth - Attracts speculative biotech investors seeking asymmetric upside from clinical trial success, with typical 3-5x return potential if Phase III succeeds but near-total loss if trials fail. The -40.9% one-year return and 19% three-month bounce reflect high volatility around binary events. Not suitable for value or income investors given no earnings, dividends, or tangible asset base. Momentum traders enter around trial readout catalysts.